Hiroshi Matsumoto

Saitama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Retrograde En Bloc Apocrine Glandectomy for Treatment of Osmidrosis.

Retrograde En Bloc Apocrine Glandectomy for Treatment of Osmidrosis.

Journal: Journal of plastic and reconstructive surgery

Published: May 07, 2025

Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial.

Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial.

Journal: British journal of cancer

Published: March 06, 2025

Significance of MUC1 and β-Catenin Localization in Mucinous Carcinoma of the Breast.

Significance of MUC1 and β-Catenin Localization in Mucinous Carcinoma of the Breast.

Journal: Anticancer research

Published: March 02, 2024

Using the DNA Integrity Number to Analyze DNA Quality in Specimens Collected from Liquid-Based Cytology after Fine-Needle Aspiration of Breast Tumors and Lesions.

Using the DNA Integrity Number to Analyze DNA Quality in Specimens Collected from Liquid-Based Cytology after Fine-Needle Aspiration of Breast Tumors and Lesions.

Journal: Acta cytologica

Published: January 22, 2024

Trends and issues in clinical research on satisfaction and quality of life after mastectomy and breast reconstruction: a 5-year scoping review.

Trends and issues in clinical research on satisfaction and quality of life after mastectomy and breast reconstruction: a 5-year scoping review.

Journal: International journal of clinical oncology

Published: February 24, 2023

Oncofertility-related psycho-educational therapy for young adult patients with breast cancer and their partners: Randomized controlled trial.

Oncofertility-related psycho-educational therapy for young adult patients with breast cancer and their partners: Randomized controlled trial.

Journal: Cancer

Published: October 05, 2022

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer.

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer.

Journal: Scientific reports

Published: August 01, 2021

Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer.

Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer.

Journal: Scientific reports

Published: January 27, 2021

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: July 28, 2020

β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.

β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.

Journal: Breast cancer research and treatment

Published: May 04, 2019

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.

Journal: PloS one

Published: February 13, 2019

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.

Journal: Scientific reports

Published: February 01, 2019

Showing 1-12 of 36

Last Updated: 09/26/2026